Presentation at International IgA Nephropathy Network Meeting Highlighting Supportive Post-hoc Analysis of the NEFIGAN Study

STOCKHOLM, Oct. 1, 2018 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced supportive post-hoc results from its clinical Phase 2b study NEFIGAN of the company's lead candidate Nefecon, presented by Prof. Bengt Fellström at the International IgA...

from PR Newswire: //https://ift.tt/2IuEE9I